Hypochondroplasia
MONDO:0007793Hypochondroplasia is characterized by disproportionate short stature, mild lumbar lordosis and limited extension of the elbow joints.
Also known as: hypochondroplasia, HCH
8 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Could a daily pill boost growth in kids with hypochondroplasia?
Disease control ENROLLING_BY_INVITATIONThis study tests an oral drug called infigratinib in children with hypochondroplasia, a condition that causes short stature. The trial has two parts: first, all children receive the drug to see if it safely increases their growth rate; then, some will switch to a placebo to confi…
Phase: PHASE2, PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Hope for kids with rare bone disorder: new drug shows promise in Long-Term trial
Disease control ENROLLING_BY_INVITATIONThis study is for children with hypochondroplasia, a condition that causes short stature and bone differences. Researchers are testing a drug called infigratinib to see if it is safe and helps improve growth over the long term. Participants must have already completed a previous …
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to help kids with rare genetic short stature grow taller
Disease control OngoingThis study tests a drug called vosoritide in 56 children with short stature caused by certain genetic conditions. The drug targets the growth plate to help children grow faster. Participants are observed for 6 months, then treated with daily injections for 12 months to check safe…
Phase: PHASE2 • Sponsor: Andrew Dauber • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug aims to help short-statured children grow taller
Disease control OngoingThis study tests a drug called vosoritide to see if it can safely help children with hypochondroplasia grow faster. About 80 children aged 3 to 17 with a confirmed genetic diagnosis and very short stature will receive either the drug or a placebo for one year. The main goal is to…
Phase: PHASE3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC